Analyst Consensus ?
ConsensusBuy6 ratings
Bullish583.3%
Neutral116.7%
Bearish00.0%
Takeda Pharmaceutical Company Limited · TAK · FY2026 Q1 · Calendar Q3 2026
Takeda Maintains FY2026 Guidance as Q1 Results Stay on Track
Management described a steady start to FY2026: core revenue declined 0.5% at constant exchange rates, but the company said it remains on track with full-year guidance. The investment case in the supplied analysis rests on execution of upcoming launches and continued cost savings, alongside the existing in-line portfolio.
Reported Before market openNYSEHealthcare
$66.81B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.23
Consensus $0.17
EPS surprise
+33.2%
Reported versus consensus
Reported revenue
$7.66B
Consensus $7.13B
Revenue surprise
+7.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-2.8%
Event window
SPY move
+1.7%
Same window
Abnormal move
-4.5%
Stock minus SPY
Volume
1.5×
Versus trailing sessions
Subsequent drift
+4.5%
Up to 20 sessions
TAKSPY benchmark
Ask FN2 about TAK FY2026 Q1
Transcript, numbers and history already loaded
Why did TAK fall 2.8% after beating EPS estimates in FY2026 Q1?What changed in TAK's guidance and outlook in FY2026 Q1?Give me the bull and bear case for TAK after FY2026 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Takeda reaffirmed full-year guidance and highlighted the first China approval of ORZEYFUL, plans for launches of ORZEYFUL and rusfertide in H2 2026 and zasocitinib in H1 2027, and a plasma-operations collaboration in Indonesia.
Guidance delta
Maintained. The supplied transcript analysis says management reaffirmed full-year guidance; no change to guidance was reported.
Key takeaways
- Management said FY2026 Q1 was on track with full-year guidance despite a 0.5% decline in core revenue at constant exchange rates.
- The company highlighted planned launches of ORZEYFUL, rusfertide and zasocitinib over the next 12–18 months.
- The transcript analysis cites continued ENTYVIO growth and transformation savings as support for the in-line portfolio and growth investment.
Management priorities
- Execute the planned launches and support market access for ORZEYFUL, rusfertide and zasocitinib.
- Advance late-stage pipeline readouts, including TAK-928 and TAK-360.
- Continue transformation savings and develop the plasma business in Indonesia.
Follow TAK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Outperform | Outperform | Maintain | May 16, 2023 |
| B of A Securities | Buy | Neutral | Upgrade | Mar 16, 2023 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Jul 19, 2022 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Oct 7, 2021 |
| JP Morgan | Overweight | Overweight | Maintain | Mar 11, 2020 |
| Jefferies | Buy | Buy | Maintain | Sep 24, 2019 |
Track every rating change on TAK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationTakeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions.…
Historical context
All TAK earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the TAK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-04T15:12:59.924948+00:00
- FN2 earnings calendar · 2026-09-04T01:23:15.205020+00:00
- Polygon adjusted daily market bars · 2026-11-01T20:40:44.558925+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.